39
Participants
Start Date
January 18, 2022
Primary Completion Date
July 31, 2024
Study Completion Date
December 31, 2025
Sintilimab 200mg+MB07133 600mg
"1. Adopting the classic 3+3 scheme design, 3 dose groups, with a cycle of 21 days. On the first day of each cycle, a single infusion of Sintilimab is given, and MB07133 is given for 7 consecutive days after a 2-hour interval between infusion initiation.~2. Sintilimab 200mg+MB07133 1800mg, recruiting 30 subjects,the administration method is as 1."
RECRUITING
The First Hospital of Jilin University, Jilin
The First Hospital of Jilin University
OTHER
Xi'an Xintong Pharmaceutical Research Co.,Ltd.
OTHER